Tau antibody and neurodegeneration reagents: choose by the species that matters

Designing the extraction and the panel

1. Fractionate by solubility deliberately. Sequential extraction into soluble and insoluble fractions is the core technique here, because the pathological species partitions into the fraction most protocols discard. Blot both and show both.
2. Name the species the reagent detects. Total, phosphorylated at a defined site, conformational and truncated reagents exist for the same protein and report different things. Buy against the species in the hypothesis, and say which in the methods.
3. Preserve modification state at collection. Phosphorylation is lost quickly post mortem and in a warm lysate. Handling time, temperature and inhibitor presence dominate the measurement of any phosphorylated species.
4. Read glial markers as state dependent. Markers used to identify glial populations change with activation, so a reduced signal can mean fewer cells or a changed state. Pair an identity marker with a state marker before drawing a conclusion about numbers.
5. Confirm aggregates by more than a blot. Insolubility on a blot is suggestive; a conformation specific reagent, a filter trap assay or imaging of inclusions is what supports an aggregation claim.

Solubility is the axis

The organising principle of this field is that proteins move from a soluble, functional pool into an insoluble, aggregated one. Every technical decision, extraction buffer, centrifugation, whether the pellet is analysed, follows from that.

Report both fractions and the extraction conditions. A result from one fraction with no description of the other is uninterpretable to anyone trying to reproduce it.

Post mortem tissue is its own discipline

Interval to fixation, agonal state and storage all change what is measurable, particularly for modified species. Those variables frequently exceed the disease effect being studied.

Record them for every case, match them between groups, and treat them as covariates. Studies that do this reproduce; studies that do not, generally do not.

A fus antibody and the localisation that is the readout

In this biology the question is not how much protein there is but where it is, since the nuclear to cytoplasmic shift and the inclusions are the phenotype. A fus antibody is therefore an imaging reagent first, with a fractionation blot as support, and a figure needs a nuclear marker in the same field. Detergent insoluble fractions are where the aggregated pool is, and it is lost by a soluble lysate alone.

An smn antibody and the gems it is counted in

SMN protein is read as nuclear foci whose number per nucleus is the measurement in spinal muscular atrophy work, so an smn antibody needs a stated scoring rule and a resolution that resolves them. Levels on a blot are the other half, and the two together are what a therapy experiment reports. Patient derived lines with known protein levels are the controls that make a small difference believable.

A neurofilament antibody and an nf-h antibody name a subunit

Neurofilaments are built from light, medium and heavy subunits, and a neurofilament antibody sold without a subunit is ambiguous, while an nf-h antibody names one. The heavy subunit is also heavily phosphorylated, so phospho dependent clones exist and give a different pattern in axons. For a blot the apparent mass moves with phosphorylation, which is why the datasheet's own figure is the reference.

A doublecortin antibody for immature neurons

Doublecortin marks migrating and newly born neurons and disappears as they mature, so a doublecortin antibody is a neurogenesis reagent whose signal is expected to be sparse. That sparseness makes the negative control and the imaging settings decisive, since a raised gain turns background into cells. A region known to carry immature neurons in the same section is the internal positive control worth including.

A myelin basic protein antibody and the compaction it reports

Myelin basic protein is abundant and tightly packed, which is why a myelin basic protein antibody often needs stronger permeabilisation or delipidation than a cytoplasmic target, and why a weak first attempt is usually a penetration problem. Several isoforms exist from one gene, so a blot shows a family of bands rather than one. White matter in the same section is the control the pattern is judged against.

A tmem106b antibody and the lysosomal membrane it sits in

This lysosomal membrane protein is glycosylated and multipass, so a tmem106b antibody reads as a broad or laddered band rather than a sharp one, and a deglycosylation lane is what shows that is the protein. It is read against a lysosomal marker in imaging, since the compartment is the claim. Boiling a membrane protein aggregates it, so sample preparation is where most of these blots are lost.

Common questions

Why is my target absent from the lysate?

Because it went into the pellet. In this field the insoluble fraction is frequently the sample that matters, and a protocol that discards it will report a loss where there was a redistribution.

Total or phospho reagent?

Both, from the same sample. The phosphorylated species is only interpretable as a fraction of the total, and treatments and disease states change both.

Does a glial marker such as a TREM2 antibody count cells?

Only if the marker is state independent, which most are not. Activation changes expression, so an apparent change in cell number may be a change in phenotype. Use two markers with different regulation.

Browse by service class

• Compare Gene synthesis on advertised prices